Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Intermittent Atorvastatin for LDL-c Variability and Trained Immunity
NCT05790499Completed
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of atorvastatin in hypercholesterolemia. Primary endpoint: Changes in Low-Density Lipoprotein Cholesterol levels at 16 weeks. Started Mar 2023; status: completed.
02
Drugs
atorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05790499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790499.